Clarification: Drug Risk in Patients with Glaucoma
The Medical Letter article on Detrol LA and Ditropan XL (vol.43, page 28, April 2, 2001) stated that these drugs should not be used in patients with glaucoma. That statement is misleading because anticholinergic or antimuscarinic drugs present a risk only to patients with untreated angle-closure (also called narrow-angle) glaucoma, which accounts for 10% of glaucomas in the USA. These drugs have no effect on the more common open-angle glaucoma, or on angle-closure glaucoma that has been treated by laser iridectomy.
This article has been freely provided.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Clarification: Drug Risk in Patients with Glaucoma
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1106
Article Code: 1106c
Date: June 11, 2001
Volume: 43
Page: 52
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1106
Article Code: 1106c
Date: June 11, 2001
Volume: 43
Page: 52
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article.This article is not available for purchase.